Another big patent expiry, limited gains for generics -

13-12-2013 Moneycontrol.comComments (0)

CymbaltaEli LillyGenerics

... limited gains for generics. Latest patent expiration of Eli Lily's anti-depressant drug Cymbalta, which had annual US sales of USD 5.5 billion, has not materialised as anticipated by the Indian generic drug makers, reports CNBC TV18's Archana Shukla.


Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top